{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T18:17:59Z","timestamp":1773771479591,"version":"3.50.1"},"reference-count":38,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Harm Reduct J"],"DOI":"10.1186\/s12954-025-01335-4","type":"journal-article","created":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T11:47:51Z","timestamp":1763466471000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Harm reduction in the fourth wave of the opioid epidemic: A case series investigation of the effectiveness of definitive vs presumptive urine drug testing for opioid use disorder with co-occurring polysubstance use"],"prefix":"10.1186","volume":"22","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-8426-7110","authenticated-orcid":false,"given":"Richard H.","family":"Cales","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Campbell L.","family":"Bishop","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5214-2885","authenticated-orcid":false,"given":"Martin R.","family":"Huecker","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6023-0594","authenticated-orcid":false,"given":"Jacob","family":"Shreffler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4369-1334","authenticated-orcid":false,"given":"Matthew D.","family":"Eisenstat","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D. J.","family":"Troutt","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2025,11,18]]},"reference":[{"key":"1335_CR1","doi-asserted-by":"publisher","unstructured":"Garnett MF, Mini\u00f1o AM. Drug overdose deaths in the United States, 2003\u20132023. NCHS Data Brief, No. 522. Hyattsville, MD: National Center for Health Statistics. 2024. https:\/\/doi.org\/10.15620\/cdc\/170565","DOI":"10.15620\/cdc\/170565"},{"issue":"3","key":"1335_CR2","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1111\/j.1465-3362.2011.00291.x","volume":"30","author":"JC Maxwell","year":"2011","unstructured":"Maxwell JC. The prescription drug epidemic in the united states: a perfect storm. Drug Alcohol Rev. 2011;30(3):264\u201370. https:\/\/doi.org\/10.1111\/j.1465-3362.2011.00291.x.","journal-title":"Drug Alcohol Rev"},{"key":"1335_CR3","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1016\/j.drugalcdep.2018.08.029","volume":"193","author":"MS Ellis","year":"2018","unstructured":"Ellis MS, Kasper ZA, Cicero TJ. Twin epidemics: the surging rise of methamphetamine use in chronic opioid users. Drug Alcohol Depend. 2018;193:14\u201320. https:\/\/doi.org\/10.1016\/j.drugalcdep.2018.08.029.","journal-title":"Drug Alcohol Depend"},{"issue":"2","key":"1335_CR4","doi-asserted-by":"publisher","first-page":"244","DOI":"10.2105\/AJPH.2019.305412","volume":"110","author":"TJ Cicero","year":"2020","unstructured":"Cicero TJ, Ellis MS, Kasper ZA. Polysubstance use: a broader Understanding of substance use during the opioid crisis. Am J Public Health. 2020;110(2):244\u201350. https:\/\/doi.org\/10.2105\/AJPH.2019.305412.","journal-title":"Am J Public Health"},{"issue":"4","key":"1335_CR5","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1097\/yco.0000000000000717","volume":"34","author":"D Ciccarone","year":"2021","unstructured":"Ciccarone D. The rise of illicit fentanyls, stimulants and the fourth wave of the opioid overdose crisis. Curr Opin Psychiatry. 2021;34(4):344\u201350. https:\/\/doi.org\/10.1097\/yco.0000000000000717.","journal-title":"Curr Opin Psychiatry"},{"issue":"7","key":"1335_CR6","doi-asserted-by":"publisher","first-page":"e2116391","DOI":"10.1001\/jamanetworkopen.2021.16391","volume":"4","author":"S Slavova","year":"2021","unstructured":"Slavova S, Quesinberry D, Hargrove S, Rock P, Brancato C, Freeman PR, et al. Trends in drug overdose mortality rates in Kentucky, 2019\u20132020. JAMA Netw Open. 2021;4(7):e2116391. https:\/\/doi.org\/10.1001\/jamanetworkopen.2021.16391.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"1335_CR7","doi-asserted-by":"publisher","first-page":"e192851","DOI":"10.1001\/jamanetworkopen.2019.2851","volume":"2","author":"L LaRue","year":"2019","unstructured":"LaRue L, Twillman RK, Dawson E, Whitley P, Frasco MA, Huskey A, et al. Rate of Fentanyl positivity among urine drug test results positive for cocaine or methamphetamine. JAMA Netw Open. 2019;2(4):e192851. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.2851.","journal-title":"JAMA Netw Open"},{"issue":"1","key":"1335_CR8","doi-asserted-by":"publisher","first-page":"e1918514","DOI":"10.1001\/jamanetworkopen.2019.18514","volume":"3","author":"RK Twillman","year":"2020","unstructured":"Twillman RK, Dawson E, LaRue L, Guevara MG, Whitley P, Huskey A. Evaluation of trends of near-real-time urine drug test results for methamphetamine, cocaine, heroin, and Fentanyl. JAMA Netw Open. 2020;3(1):e1918514. https:\/\/doi.org\/10.1001\/jamanetworkopen.2019.18514.","journal-title":"JAMA Netw Open"},{"key":"1335_CR9","doi-asserted-by":"publisher","unstructured":"LaRue L, Guevara MG, Whitley P, Dawson E, Twillman RK, Huskey A. (2021). The cyclical and evolving nature of methamphetamine use: An evaluation of near-real-time urine drug test results. J Addict Med. 2021;15(5):396\u2013405. https:\/\/doi.org\/10.1097\/ADM.0000000000000778","DOI":"10.1097\/ADM.0000000000000778"},{"issue":"34","key":"1335_CR10","doi-asserted-by":"publisher","first-page":"1136","DOI":"10.15585\/mmwr.mm7034a2","volume":"70","author":"S Liu","year":"2021","unstructured":"Liu S, O\u2019Donnell J, Gladden RM, McGlone L, Chowdhury F. Trends in nonfatal and fatal overdoses involving benzodiazepines\u201438 States and the district of Columbia, 2019\u20132020. MMWR Morb Mortal Wkly Rep. 2021;70(34):1136\u201341.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"17","key":"1335_CR11","doi-asserted-by":"publisher","first-page":"1819","DOI":"10.1001\/jama.2018.2844","volume":"319","author":"CM Jones","year":"2018","unstructured":"Jones CM, Einstein EB, Compton WM. Changes in synthetic opioid involvement in drug overdose deaths in the United States, 2010\u20132016. JAMA. 2018;319(17):1819\u201321. https:\/\/doi.org\/10.1001\/jama.2018.2844.","journal-title":"JAMA"},{"issue":"224","key":"1335_CR12","doi-asserted-by":"publisher","first-page":"2214","DOI":"10.1056\/NEJMp2302857","volume":"388","author":"ND Volkow","year":"2023","unstructured":"Volkow ND, Califf RM, Sokolowska M, Tabak LA, Compton WM. Testing for fentanyl\u2014urgent need for practice relevant and public health research. NEJM. 2023;388(224):2214\u20137. https:\/\/doi.org\/10.1056\/NEJMp2302857.","journal-title":"NEJM"},{"issue":"1","key":"1335_CR13","doi-asserted-by":"publisher","first-page":"61","DOI":"10.5055\/jom.2015.0253","volume":"11","author":"KL Kirsh","year":"2015","unstructured":"Kirsh KL, Heit HA, Huskey A, Strickland J, Egan K, Passik SD. Trends in drug use from urine drug testing of addiction treatment clients. J Opioid Manag. 2015;11(1):61\u20138. https:\/\/doi.org\/10.5055\/jom.2015.0253.","journal-title":"J Opioid Manag"},{"issue":"10","key":"1335_CR14","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1080\/10408444.2018.1553935","volume":"48","author":"AG Barthwell","year":"2018","unstructured":"Barthwell AG, Allgaier J, Egli K. Definitive urine drug testing in office-based opioid treatment: a literature review. Crit Rev Toxicol. 2018;48(10):829\u201352. https:\/\/doi.org\/10.1080\/10408444.2018.1553935.","journal-title":"Crit Rev Toxicol"},{"key":"1335_CR15","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1097\/FTD.0000000000000841","volume":"43","author":"GA McMillin","year":"2021","unstructured":"McMillin GA, Johnson-Davis KL, Kelly BN, Scott B, Yang YK. Impact of the opioid epidemic on drug testing. Ther Drug Monit. 2021;43:14\u201324. https:\/\/doi.org\/10.1097\/FTD.0000000000000841.","journal-title":"Ther Drug Monit"},{"key":"1335_CR16","doi-asserted-by":"publisher","unstructured":"Jarvis M, Williams J, Hurford M, Lindsay D, Lincoln P, Giles L et al. Appropriate use of drug testing in clinical addiction medicine. J Addict Med. 2017;11(3):163\u2013173. Supplement accessed January 27, 2022. http:\/\/links.lww.com\/jam\/A56https:\/\/doi.org\/10.1097\/ADM.0000000000000323","DOI":"10.1097\/ADM.0000000000000323"},{"key":"1335_CR17","unstructured":"Centers for Disease Control. Drug overdose mortality by state, 2019. 2019. Accessed 14 Oct 2022. https:\/\/www.cdc.gov\/nchs\/pressroom\/sosmap\/drug_poisoning_mortality\/drug_poisoning.htm"},{"key":"1335_CR18","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1016\/j.drugpo.2018.08.006","volume":"64","author":"J McEachern","year":"2019","unstructured":"McEachern J, Adye-White L, Priest KC, Moss E, Gorfinkel L, Wood E, et al. Lacking evidence for the association between frequent urine drug screening and health outcomes of persons on opioid agonist therapy. Int J Drug Policy. 2019;64:30\u20133. https:\/\/doi.org\/10.1016\/j.drugpo.2018.08.006.","journal-title":"Int J Drug Policy"},{"key":"1335_CR19","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.drugalcdep.2013.12.009","volume":"136","author":"J Dupouy","year":"2014","unstructured":"Dupouy J, M\u00e9mier V, Catala H, Lavit M, Oustric S, Lapeyre-Mestre M. Does urine drug abuse screening help for managing patients? A systematic review. Drug Alcohol Depend. 2014;136:11\u201320. https:\/\/doi.org\/10.1016\/j.drugalcdep.2013.12.009.","journal-title":"Drug Alcohol Depend"},{"issue":"1","key":"1335_CR20","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1016\/j.ajo.2010.08.047","volume":"151","author":"JH Kempen","year":"2011","unstructured":"Kempen JH. Appropriate use and reporting of uncontrolled case series in the medical literature. Am J Ophthalmol. 2011;151(1):7\u201310. https:\/\/doi.org\/10.1016\/j.ajo.2010.08.047.","journal-title":"Am J Ophthalmol"},{"key":"1335_CR21","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/s12871-016-0265-3","volume":"16","author":"D Faraoni","year":"2016","unstructured":"Faraoni D, Schaefer ST. Randomized controlled trials vs. observational studies: why not just live together? BMC Anesthesiol. 2016;16:1\u20134. https:\/\/doi.org\/10.1186\/s12871-016-0265-3.","journal-title":"BMC Anesthesiol"},{"issue":"21","key":"1335_CR22","doi-asserted-by":"publisher","first-page":"1845","DOI":"10.1001\/jama.2024.7741","volume":"331","author":"IJ Dahabreh","year":"2024","unstructured":"Dahabreh IJ, Bibbins-Domingo K. Causal inference about the effects of interventions from observational studies in medical journals. JAMA. 2024;331(21):1845\u201353. https:\/\/doi.org\/10.1001\/jama.2024.7741.","journal-title":"JAMA"},{"key":"1335_CR23","doi-asserted-by":"publisher","DOI":"10.1001\/jamanetworkopen.2022.15425","author":"P Whitley","year":"2022","unstructured":"Whitley P, LaRue L, Fernandez SA, Passik SD, Dawson E, Jackson RD. Analysis of urine drug test results from substance use disorder treatment practices and overdose mortality rates, 2013\u20132020. JAMA Netw Open. 2022. https:\/\/doi.org\/10.1001\/jamanetworkopen.2022.15425.","journal-title":"JAMA Netw Open"},{"issue":"4","key":"1335_CR24","doi-asserted-by":"publisher","first-page":"269","DOI":"10.1097\/YCO.0000000000000069","volume":"27","author":"JP Connor","year":"2014","unstructured":"Connor JP, Gullo MJ, White A, Kelly AB. Polysubstance use: diagnostic challenges, patterns of use and health. Curr Opin Psychiatry. 2014;27(4):269\u201375. https:\/\/doi.org\/10.1097\/YCO.0000000000000069.","journal-title":"Curr Opin Psychiatry"},{"key":"1335_CR25","doi-asserted-by":"publisher","unstructured":"Bhalla IP, Stefanovics EA, Rosenheck RA. Clinical epidemiology of single vs. multiple substance use disorders\u2014polysubstance use disorder. Med Care. 2017;55(9, Suppl 9 Suppl 2):S24-S32. https:\/\/doi.org\/10.1097\/MLR.0000000000000731","DOI":"10.1097\/MLR.0000000000000731"},{"key":"1335_CR26","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1186\/s12954-023-00816-8","volume":"20","author":"J Ondocsin","year":"2023","unstructured":"Ondocsin J, Holm N, Mars SG, Ciccarone D. The motives and methods of methamphetamine and \u2018heroin\u2019 co-use in West Virginia. Harm Reduct J. 2023;20:88.","journal-title":"Harm Reduct J"},{"issue":"43","key":"1335_CR27","doi-asserted-by":"publisher","first-page":"1197","DOI":"10.15585\/mmwr.mm6643e1","volume":"66","author":"JK O\u2019Donnell","year":"2017","unstructured":"O\u2019Donnell JK, Halpin J, Mattson CL, Goldberger BA, Gladden RM. Deaths involving Fentanyl, Fentanyl analogs, and U-47700\u201310 States, July\u2013December, 2016. MMWR Morb Mortal Wkly Rep. 2017;66(43):1197\u2013202. https:\/\/doi.org\/10.15585\/mmwr.mm6643e1.","journal-title":"MMWR Morb Mortal Wkly Rep"},{"issue":"1","key":"1335_CR28","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1177\/0033354919887741","volume":"135","author":"VM Singh","year":"2020","unstructured":"Singh VM, Browne T, Montgomery J. The emerging role of toxic adulterants in street drugs in the US illicit opioid crisis. Public Health Rep. 2020;135(1):6\u201310. https:\/\/doi.org\/10.1177\/0033354919887741.","journal-title":"Public Health Rep"},{"key":"1335_CR29","unstructured":"Centers for Medicare & Medical Services. Controlled substance monitoring and drugs of abuse testing. L34645; R19; 10\/01\/2021. 2021. https:\/\/www.cms.gov\/medicare-coverage-database\/view\/lcd.aspx"},{"issue":"4","key":"1335_CR30","first-page":"301","volume":"37","author":"GM Reisfield","year":"2007","unstructured":"Reisfield GM, Salazar E, Bertholf RL. Rational use and interpretation of urine drug testing in chronic opioid therapy. Ann Clin Lab Sci. 2007;37(4):301\u201314.","journal-title":"Ann Clin Lab Sci"},{"issue":"6","key":"1335_CR31","doi-asserted-by":"publisher","first-page":"700","DOI":"10.3109\/10826084.2015.1135953","volume":"51","author":"AG Barthwell","year":"2016","unstructured":"Barthwell AG. Clinical and public health considerations in urine drug testing to identify and treat substance use. Subst Use Misuse. 2016;51(6):700\u201310. https:\/\/doi.org\/10.3109\/10826084.2015.1135953.","journal-title":"Subst Use Misuse"},{"issue":"3","key":"1335_CR32","first-page":"273","volume":"13","author":"A Pesce","year":"2010","unstructured":"Pesce A, Rosenthal M, West R, West C, Crews B, Mikel C, et al. An evaluation of the diagnostic accuracy of liquid chromatography-tandem mass spectrometry versus immunoassay drug testing in pain patients. Pain Phys. 2010;13(3):273\u201381.","journal-title":"Pain Phys"},{"issue":"12","key":"1335_CR33","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1001\/jamapsychiatry.2021.2588","volume":"78","author":"B Han","year":"2021","unstructured":"Han B, Compton WM, Jones CM, Einstein EB, Volkow ND. Methamphetamine use, methamphetamine use disorder, and associated overdose deaths among US adults. JAMA Psychiatry. 2021;78(12):1329\u201342. https:\/\/doi.org\/10.1001\/jamapsychiatry.2021.2588.","journal-title":"JAMA Psychiatry"},{"key":"1335_CR34","doi-asserted-by":"publisher","first-page":"108264","DOI":"10.1016\/j.drugalcdep.2020.108264","volume":"217","author":"JD Stanton","year":"2020","unstructured":"Stanton JD, Whitley P, LaRue L, Bundy WL, Dawson E, Huskey A. Fentanyl analog positivity among near-real-time urine drug test results in patients seeking health care. Drug Alcohol Depend. 2020;217:108264. https:\/\/doi.org\/10.1016\/j.drugalcdep.2020.108264.","journal-title":"Drug Alcohol Depend"},{"key":"1335_CR35","unstructured":"Commonwealth of Massachusetts Office of the State Auditor. Office of Medicaid. (MassHealth) Medicaid claims for drug screenings. Boston, MA. April 2013. 2012-1374-3C. 2013. Accessed 6 Feb 2022. https:\/\/www.mass.gov\/doc\/office-of-medicaid-masshealth-medicaid-claims-for-drug-screenings\/download"},{"key":"1335_CR36","unstructured":"Justice News. Millennium Health agrees to pay $256 million to resolve allegations of unnecessary drug and genetic testing and illegal remuneration to physicians. 2015. Accessed 6 Feb 2022. https:\/\/www.justice.gov\/opa\/pr\/millennium-health-agrees-pay-256-million-resolve-allegations-unnecessary-drug-and-genetic"},{"key":"1335_CR37","unstructured":"Department of Health and Human Services. Office of Inspector General. Opportunities exist for CMS and its Medicare contractors to strengthen program safeguards to prevent and detect improper payments for drug testing services. A-09-20-03017. June 2021. 2021. Accessed 6 Feb 2022. https:\/\/oig.hhs.gov\/oas\/reports\/region9\/92003017.pdf"},{"key":"1335_CR38","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.drugpo.2018.08.007","volume":"63","author":"NC Peiper","year":"2019","unstructured":"Peiper NC, Clarke SD, Vincent LB, Ciccarone D, Kral AH, Zibbell JE. Fentanyl test strips as an opioid overdose prevention strategy: findings from a syringe services program in the southeastern United States. Int J Drug Policy. 2019;63:122\u20138. https:\/\/doi.org\/10.1016\/j.drugpo.2018.08.007.","journal-title":"Int J Drug Policy"}],"container-title":["Harm Reduction Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01335-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12954-025-01335-4","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12954-025-01335-4.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,3,17]],"date-time":"2026-03-17T15:06:04Z","timestamp":1773759964000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12954-025-01335-4"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,11,18]]},"references-count":38,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2025,12]]}},"alternative-id":["1335"],"URL":"https:\/\/doi.org\/10.1186\/s12954-025-01335-4","relation":{},"ISSN":["1477-7517"],"issn-type":[{"value":"1477-7517","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,11,18]]},"assertion":[{"value":"29 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 November 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 August 2025","order":5,"name":"change_date","label":"Change Date","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Update","order":6,"name":"change_type","label":"Change Type","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The \u201cpolysubstance use\u201d appears twice as a subheading under the Results section and now has been corrected.","order":7,"name":"change_details","label":"Change Details","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Ethics approval\u2014including written, informed patient consent\u2014was approved by the University of Louisville Institutional Review Board (Reference #720177).","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"Richard Cales, MD, reports a relationship with NuLease Medical Solutions, LLC, that includes consulting or advisory and non-financial support. Limited to private contractor (non-employee) as Chief Medical Officer, NuLease Medical Solutions, LLC. Spouse of Shannon C. Cales, MHA, who is sole owner of NuLease Medical Solutions, LLC. D. J. Troutt, MA, reports a relationship with NuLease Medical Solutions, LLC, that includes employment.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"187"}}